Scarica l'app Stockscreener
158.43
3.31%
5.07
Dopo l'orario di chiusura:
158.43
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia
Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - The Manila Times
Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE - MarketBeat
Belite Bio, Inc. ADR (BLTE) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Belite Bio, Inc. ADR (BLTE) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Belite Bio, Inc. ADR (BLTE) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - markets.businessinsider.com
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease - Yahoo Finance
Belite Bio at Piper Sandler ophthalmology day: drug data support filing - Investing.com India
Belite Bio Slumps As Market Turmoil Trumps Drug Hopes - TipRanks
How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story - Sahm
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Frontier tech research, news & data - MLQ.ai
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (BLTE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):